Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee

TY - JOUR

T1 - Management of primary hypothyroidism

T2 - statement by the British Thyroid Association Executive Committee

AU - Okosieme, Onyebuchi

AU - Gilbert, Jackie

AU - Abraham, Prakash

AU - Boelaert, Kristien

AU - Dayan, Colin

AU - Gurnell, Mark

AU - Leese, Graham

AU - McCabe, Christopher

AU - Perros, Petros

AU - Smith, Vicki

AU - Williams, Graham

AU - Vanderpump, Mark

PY - 2016/6

Y1 - 2016/6

N2 - The management of primary hypothyroidism with levothyroxine (L-T4) is simple, effective and safe, and most patients report improved well-being on initiation of treatment. However, a proportion of individuals continue to suffer with symptoms despite achieving adequate biochemical correction. The management of such individuals has been the subject of controversy and of considerable public interest. The American Thyroid Association (ATA) and the European Thyroid Association (ETA) have recently published guidelines on the diagnosis and management of hypothyroidism. These guidelines have been based on extensive reviews of the medical literature and include sections on the role of combination therapy with L-T4 and liothyronine (L-T3) in individuals who are persistently dissatisfied with L-T4 therapy. This position statement by the British Thyroid Association (BTA) summarises the key points in these guidelines and makes recommendations on the management of primary hypothyroidism based on the current literature, review of the published positions of the ETA and ATA, and in line with best principles of good medical practice. The statement is endorsed by the Association of Clinical Biochemistry, (ACB), British Thyroid Foundation, (BTF), Royal College of Physicians (RCP) and Society for Endocrinology (SFE).

AB - The management of primary hypothyroidism with levothyroxine (L-T4) is simple, effective and safe, and most patients report improved well-being on initiation of treatment. However, a proportion of individuals continue to suffer with symptoms despite achieving adequate biochemical correction. The management of such individuals has been the subject of controversy and of considerable public interest. The American Thyroid Association (ATA) and the European Thyroid Association (ETA) have recently published guidelines on the diagnosis and management of hypothyroidism. These guidelines have been based on extensive reviews of the medical literature and include sections on the role of combination therapy with L-T4 and liothyronine (L-T3) in individuals who are persistently dissatisfied with L-T4 therapy. This position statement by the British Thyroid Association (BTA) summarises the key points in these guidelines and makes recommendations on the management of primary hypothyroidism based on the current literature, review of the published positions of the ETA and ATA, and in line with best principles of good medical practice. The statement is endorsed by the Association of Clinical Biochemistry, (ACB), British Thyroid Foundation, (BTF), Royal College of Physicians (RCP) and Society for Endocrinology (SFE).

UR - https://www.scopus.com/pages/publications/84933059930

U2 - 10.1111/cen.12824

DO - 10.1111/cen.12824

M3 - Article

C2 - 26010808

AN - SCOPUS:84933059930

SN - 0300-0664

VL - 84

SP - 799

EP - 808

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - 6

ER -